Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.96 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.96 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070561 | 0.98 | CYP4F2 (1.00) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL22098346 | 0.98 | CYP4F2 (1.00) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL20730318 | 0.98 | CYP4F2 (1.00) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL22070755 | 0.98 | CYP4F2 (1.00) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL3289027 | 0.98 | CYP4F2 (0.92) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17756701 | 0.93 | CYP4F2 (0.83) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL6257314 | 0.90 | CYP4F2 (0.85) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL6254544 | 0.90 | CYP4F2 (0.85) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL20597774 | 0.88 | CYP4F2 (0.81) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL2737131 | 0.86 | CYP4F2 (0.72) | CYP4F2CYP4A11PKMTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | NEUROBO PHARMACEUTICALS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| CN-111704543-A | Process and intermediates for preparing alpha, omega-dicarboxylic acid terminated dialkyl ethers | 燿石治疗公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3653598-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING , -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | Gemphire Therapeutics Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | NEUROBO PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10227285-B2 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | GEMPHIRE THERAPEUTICS INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2016077832-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016077832-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20040122089-A1 | Analogs of andandamide and arvanil have been found to act at receptors; are useful in pain management, used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications | VIRGINIA COMMONWEALTH UNIVERSITY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885PKM 1974/4885 |
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | ELOVL3, DGKI, ELOVL5 | CYP4F2 77/4885CYP4A11 235/4885PKM 1082/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885PKM 1974/4885 |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | CYP4F2 473/4885CYP4A11 154/4885PKM 1584/4885 |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | BCKDK, DGKI, DDC | CYP4F2 87/4885CYP4A11 155/4885PKM 259/4885 |
| US-10227285-B2 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | DGKI, DGKA, SQLE | CYP4F2 129/4885CYP4A11 250/4885PKM 579/4885 |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | DGKI, DGKA, SQLE | CYP4F2 129/4885CYP4A11 250/4885PKM 579/4885 |
| US-20040122089-A1 | Analogs of andandamide and arvanil have been found to act at receptors; are useful in pain management, used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications | CNR1, AVPR1A, OPRL1 | CYP4F2 4618/4885CYP4A11 2778/4885PKM 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.